JAMA Author Interviews

Infections due to multidrug-resistant organisms (MDROs) are difficult to treat with increased morbidity, mortality, length of hospitalization, and health care costs. Author Susan S. Huang, MD, MPH, from the University of California Irvine School of Medicine, joins JAMA Deputy Editor Preeti Malani, MD, MSJ, to discuss a new study that used a regional intervention to prevent MDROs. Related Content: Reducing Hospitalizations and Multidrug-Resistant Organisms via Regional Decolonization in Hospitals and Nursing Homes

The US Supreme Court will soon decide a case challenging the US Food and Drug Administration’s (FDA’s) approval of mifepristone. Author Holly Fernandez Lynch, JD, MBE, University of Pennsylvania, joins JAMA Executive Editor Gregory Curfman, MD, to discuss the science and politics surrounding this significant case. Related Content: The FDA in the Crosshairs—Science, Politics, and Abortion Provision of Medications for Self-Managed Abortion Before and After the Dobbs v Jackson Women’s Health Organization Decision Understanding the Impacts of the Supreme Court Case FDA v Alliance for Hippocratic Medicine

How did GPT-4 Vision, a model that can work with images and text as input, perform when answering clinical challenge questions from medical journals? Daniel Truhn, MD, MSc, of the University Hospital Aachen in Germany, joins JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, to discuss this topic. Related Content: Comparative Analysis of Multimodal Large Language Model Performance on Clinical Vignette Questions

Frances R. Levin is a leading expert in ADHD treatment and serves as the Kennedy Levy Professor of Psychiatry at Columbia University. In this discussion, she delves into a groundbreaking study showing that ADHD medications can significantly reduce mortality rates, including accidental poisonings. Frances highlights the importance of personalized treatment, addressing concerns around stimulant misuse and cardiovascular risks. The conversation also explores innovative research methods that enhance the understanding of ADHD's impact on behaviors and health outcomes.

Introducing JAMA's new Communicating Medicine series, JAMA Associate Editor Anne Cappola, MD, ScM, discusses strategies for delivering effective messages in the patient encounter with authors Joseph Cappella, PhD, of the University of Pennsylvania, and Richard Street, PhD, of Texas A&M University and Baylor College of Medicine. Related Content: Delivering Effective Messages in the Patient-Clinician Encounter

How will new study results inform HIV prevention in the US and globally? JAMA Deputy Editor Preeti Malani, MD, MSJ, and author Jeanne Marrazzo, MD, MPH, director of NIAID, discuss these study findings and more. Related Content: HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women

JAMA Associate Editor Romain Pirracchio, MD, MPH, discusses context and implications of the new pediatric sepsis criteria with authors Hallie Prescott, MD, MSc, of the University of Michigan and Ann Arbor VA Hospital, and Roberto Jabornisky, MD, of Northeastern National Medical School in Argentina. Related Content: Context and Implications of the New Pediatric Sepsis Criteria Transitioning From SIRS to Phoenix With the Updated Pediatric Sepsis Criteria—The Difficult Task of Simplifying the Complex

Renters who received eviction filings experienced excess mortality associated with the COVID-19 pandemic. JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, discusses a recent study that underscores the importance of studying health outcomes among marginalized populations with author Nick Graetz, PhD, from Princeton University. Related Content: Examining Excess Mortality Associated With the COVID-19 Pandemic for Renters Threatened With Eviction

Childhood death rates remain high in some areas of sub-Saharan Africa, despite global reductions in childhood mortality. JAMA Deputy Editor Preeti Malani, MD, MSJ, and author Thomas Lietman, MD, University of California, San Francisco, discuss twice-yearly azithromycin to reduce childhood mortality. Related Content: Mass Azithromycin Distribution to Prevent Child Mortality in Burkina Faso

Bivalent mRNA COVID-19 vaccines were recommended for children and adolescents aged 5 to 17 years in the US, but were they effective? JAMA Associate Editor Tracy A. Lieu, MD, MPH, spoke with author Leora R. Feldstein, PhD, US Centers for Disease Control and Prevention, about the effectiveness of bivalent COVID-19 vaccines in children and adolescents. Related Content: Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years